Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932501 | 1.00 | OGA (0.38) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL24015540 | 1.00 | OGA (0.38) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL19934115 | 0.86 | SMN1; SMN2 (0.39) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL6007557 | 0.82 | OGA (0.35) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL23130862 | 0.82 | OGA (0.35) | OGASMN1; SMN2NPSR1CYP2C9CYP2C19 | |
| SCHEMBL21413643 | 0.82 | CHRM1 (0.38) | OGAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12493083 | 0.80 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL14358246 | 0.80 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL12493075 | 0.80 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL12493078 | 0.80 | MAPK1 (0.34) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072974-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-9670166-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9670166-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-20160340319-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340319-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9290459-B1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-9290459-B1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-22 | — | — | US | disclosed |
| US-20160060230-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060231-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060231-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060230-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060230-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | OGA 4038/4885SMN1; SMN2 2865/4885NPSR1 3166/4885 |
| US-20160340319-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | OGA 4038/4885SMN1; SMN2 2865/4885NPSR1 3166/4885 |
| US-20140221335-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | OGA 4038/4885SMN1; SMN2 2865/4885NPSR1 3166/4885 |
| US-20160060231-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, MPO | OGA 4038/4885SMN1; SMN2 2865/4885NPSR1 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.